NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Up 106.1% in January

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) saw a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 2,701,762 shares, an increase of 106.1% from the January 15th total of 1,310,881 shares. Based on an average trading volume of 2,306,602 shares, the short-interest ratio is currently 1.2 days. Approximately 2.7% of the company’s stock are sold short. Approximately 2.7% of the company’s stock are sold short. Based on an average trading volume of 2,306,602 shares, the short-interest ratio is currently 1.2 days.

Institutional Investors Weigh In On NovaBay Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in NBY. Ground Swell Capital LLC bought a new position in shares of NovaBay Pharmaceuticals during the 3rd quarter valued at $25,000. Apollon Wealth Management LLC purchased a new stake in NovaBay Pharmaceuticals during the third quarter valued at $35,000. C2C Wealth Management LLC bought a new position in NovaBay Pharmaceuticals in the fourth quarter valued at about $254,000. Jane Street Group LLC purchased a new position in NovaBay Pharmaceuticals in the fourth quarter worth about $395,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in NovaBay Pharmaceuticals in the fourth quarter worth about $526,000. Institutional investors own 23.25% of the company’s stock.

NovaBay Pharmaceuticals Trading Down 10.5%

Shares of NBY opened at $0.52 on Friday. The business’s fifty day simple moving average is $5.17 and its two-hundred day simple moving average is $2.69. NovaBay Pharmaceuticals has a 12 month low of $0.46 and a 12 month high of $19.95. The company has a market cap of $67.40 million, a price-to-earnings ratio of -0.05 and a beta of 0.14.

NovaBay Pharmaceuticals shares are going to reverse split on Monday, February 23rd. The 1-5 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, February 22nd.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company’s synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay’s research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.

The company’s primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.